Cargando…
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
Gout is a chronic inflammatory disease caused by precipitation of urate crystals in the joints, kidneys, and urinary tract. Independent of urate deposition disorders, recent studies have shown a positive association between circulating uric acid (UA) levels and cardiovascular (CV) diseases. These re...
Autor principal: | Kuriyama, Satoru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066308/ https://www.ncbi.nlm.nih.gov/pubmed/31754883 http://dx.doi.org/10.1007/s10157-019-01811-9 |
Ejemplares similares
-
A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients
por: Hosoya, Tatsuo, et al.
Publicado: (2020) -
Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
por: Tanaka, Atsushi, et al.
Publicado: (2023) -
The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
por: Okui, Daisuke, et al.
Publicado: (2019) -
Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment
por: Kumagai, Yuji, et al.
Publicado: (2019) -
Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor
por: Fukase, Hiroyuki, et al.
Publicado: (2019)